TRx-237-007 Phase 3 Clinical Trial Update
Sep 04 - 2016 05:15 PM
ABERDEEN, Scotland and Singapore, 4th September 2016 – TauRx Therapeutics Ltd today announced that its TRx-237-007 Phase 3 clinical trial of the company’s second generation tau aggregation inhibitor, LMTX®, in 220 subjects with behavioural variant frontotemporal dementia (bvFTD) failed to achieve its co-primary endpoints.
TauRx Reports First Phase 3 Results for LMTX®
Jul 27 - 2016 01:00 PM
TauRx Therapeutics Ltd today announced Phase 3 clinical trial results that show treatment with LMTX®, the company’s novel tau aggregation inhibitor, had a marked beneficial effect on key measures of Alzheimer’s disease in patients with mild or moderate forms of the disease.
TauRx Phase 3 Trial TRx-237-007 in behavioural variant frontotemporal dementia
Jul 25 - 2016 11:57 AM
TauRx Therapeutics Ltd recently completed its Phase 3 clinical trial of the company’s second generation tau aggregation inhibitor, LMTX®, in behavioural variant frontotemporal dementia (bvFTD), believed to be the largest Phase 3 study ever undertaken in patients with this rare neurodegenerative disorder.
TauRx Completes US$135m Financing Round to Support Phase 3 Clinical Trials Program in Alzheimer’s and Frontotemporal Dementia
Oct 07 - 2015 09:27 PM
ABERDEEN, Scotland and SINGAPORE, 07 October 2015 – TauRx Pharmaceuticals Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer’s disease, today announced the completion of the final tranche of a US$135m equity financing that it launched in March.
TauRx Publishes Six New Journal Articles
Jun 01 - 2015 06:00 AM
With the publication of a key article in The Journal of Biological Chemistry, TauRx Pharmaceuticals Ltd. continues to build a growing body of evidence supporting the rationale for tau aggregation inhibition in the treatment of neurodegenerative diseases such as Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD). This latest of six connected papers, five of them published in the past six months, describes the robust scientific research programme behind the development of LMTX, the second-generation tau aggregation inhibitor (TAI) currently in three large global Phase 3 clinical trials.